TY - JOUR
T1 - Kidney cancer
T2 - Current and novel treatment options
AU - Jonasch, Eric
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Antiangiogenic therapies remain the standard of care in the front-line setting for renal cell carcinoma, although vascular endothelial growth factor (VEGF) blockade is not sufficient, and many patients do not respond to such treatment. With a host of approved agents, questions arise as to how best to use them in both initial and secondary treatments. Optimal sequences are currently being tested in various clinical trials. Because approximately 20% of patients exhibiting primary resistance to these anti-VEGF therapies, new therapies are needed. Novel therapies such as MET and AXL inhibitors as well as checkpoint antibodies hold promise for the future.
AB - Antiangiogenic therapies remain the standard of care in the front-line setting for renal cell carcinoma, although vascular endothelial growth factor (VEGF) blockade is not sufficient, and many patients do not respond to such treatment. With a host of approved agents, questions arise as to how best to use them in both initial and secondary treatments. Optimal sequences are currently being tested in various clinical trials. Because approximately 20% of patients exhibiting primary resistance to these anti-VEGF therapies, new therapies are needed. Novel therapies such as MET and AXL inhibitors as well as checkpoint antibodies hold promise for the future.
UR - http://www.scopus.com/inward/record.url?scp=84996538650&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84996538650&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2015.0202
DO - 10.6004/jnccn.2015.0202
M3 - Article
C2 - 25995429
AN - SCOPUS:84996538650
SN - 1540-1405
VL - 13
SP - 679
EP - 681
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
ER -